Kentucky Trust Co Acquires Shares of 145 Cencora, Inc. (NYSE:COR)

Kentucky Trust Co purchased a new position in Cencora, Inc. (NYSE:COR) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 145 shares of the company’s stock, valued at approximately $33,000.

Other hedge funds have also recently made changes to their positions in the company. Concord Wealth Partners bought a new stake in shares of Cencora in the 3rd quarter worth approximately $30,000. Householder Group Estate & Retirement Specialist LLC boosted its position in shares of Cencora by 85.2% in the 4th quarter. Householder Group Estate & Retirement Specialist LLC now owns 150 shares of the company’s stock worth $33,000 after purchasing an additional 69 shares in the last quarter. Ashton Thomas Securities LLC bought a new stake in shares of Cencora in the 3rd quarter worth approximately $41,000. Modus Advisors LLC bought a new stake in shares of Cencora in the 4th quarter worth approximately $54,000. Finally, Carolina Wealth Advisors LLC boosted its position in shares of Cencora by 366.7% in the 3rd quarter. Carolina Wealth Advisors LLC now owns 266 shares of the company’s stock worth $60,000 after purchasing an additional 209 shares in the last quarter. 97.52% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. UBS Group boosted their price target on Cencora from $275.00 to $285.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. Barclays boosted their price target on Cencora from $263.00 to $290.00 and gave the stock an “overweight” rating in a research report on Thursday, November 7th. Robert W. Baird boosted their price objective on shares of Cencora from $287.00 to $292.00 and gave the stock an “outperform” rating in a report on Thursday, November 7th. Evercore ISI boosted their price objective on shares of Cencora from $270.00 to $280.00 and gave the stock an “outperform” rating in a report on Thursday, February 6th. Finally, Mizuho assumed coverage on shares of Cencora in a report on Wednesday, December 4th. They issued an “outperform” rating and a $280.00 price objective for the company. Two equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $277.90.

Cencora Price Performance

Shares of COR opened at $243.55 on Thursday. The firm has a market cap of $47.07 billion, a PE ratio of 34.64, a P/E/G ratio of 1.49 and a beta of 0.49. The company has a current ratio of 0.92, a quick ratio of 0.53 and a debt-to-equity ratio of 16.40. The firm has a fifty day simple moving average of $238.70 and a two-hundred day simple moving average of $237.21. Cencora, Inc. has a 1-year low of $214.77 and a 1-year high of $262.26.

Cencora (NYSE:COR) last announced its earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share for the quarter, beating analysts’ consensus estimates of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. On average, equities analysts anticipate that Cencora, Inc. will post 15.36 EPS for the current year.

Cencora Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, March 3rd. Shareholders of record on Friday, February 14th will be paid a dividend of $0.55 per share. The ex-dividend date is Friday, February 14th. This represents a $2.20 dividend on an annualized basis and a yield of 0.90%. Cencora’s dividend payout ratio is presently 31.29%.

Insider Buying and Selling at Cencora

In other news, Chairman Steven H. Collis sold 21,509 shares of the company’s stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $242.16, for a total value of $5,208,619.44. Following the completion of the sale, the chairman now directly owns 306,752 shares in the company, valued at $74,283,064.32. This represents a 6.55 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, EVP Silvana Battaglia sold 1,678 shares of the company’s stock in a transaction on Friday, December 20th. The stock was sold at an average price of $228.72, for a total value of $383,792.16. Following the completion of the sale, the executive vice president now owns 20,329 shares of the company’s stock, valued at $4,649,648.88. This trade represents a 7.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 73,187 shares of company stock worth $17,790,912. Insiders own 10.80% of the company’s stock.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.